Why Arm-Pit Sweat Smells Bad ???? Know Here ….

Scientists have unravelled the mysterious mechanism behind the armpit’s ability to produce the pungent smell of body odour.

Researchers at the University of York traced the source of underarm odour to a particular enzyme in a certain microbe that lives in the human armpit.

To prove the enzyme was the chemical culprit, the scientists transferred it to an innocent member of the underarm microbe community and noted – to their delight – that it too began to emanate bad smells.

The work paves the way for more effective deodorants and antiperspirants, the scientists believe, and suggests that humans may have inherited the mephitic microbes from our ancient primate ancestors.

Continue reading

Intraventricular Methotrexate May Improve Survival in Medulloblastoma Subtypes

Adding intraventricular methotrexate to systemic chemotherapy produced favorable survival outcomes in patients with desmoplastic medulloblastoma (DMB) and medulloblastoma with extensive nodularity (MBEN), according to research published in the Journal of Clinical Oncology.

Investigators conducted a prospective trial of 87 children diagnosed with nonmetastatic medulloblastoma before the age of 4 years who were treated from 2001-2011.

At 5 years after diagnosis, the 42 DMB/MBEN patients had a 93% progression-free survival (PFS) rate, a 100% overall survival (OS) rate, and a 93% craniospinal irradiation (CSI)–free survival rate.

“Our results suggest that … poor outcomes of patients treated with systemic chemotherapy alone can be improved by the addition of intraventricular [methotrexate],” wrote Martin Mynarek, MD, of the University Medical Center Hamburg-Eppendorf (Germany), and colleagues.

Continue reading

Capsaicin Patch for Diabetic Neuropathy Foot Pain Gets Nod From FDA

A skin patch that delivers an 8% capsaicin formulation intradermally and that first received US Food and Drug Administration approval in 2009 for the treatment of postherpetic pain now has agency approval for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults, according to a company announcement on July 21.

The patch, marketed as Qutenza, is a topical, nonsystemic, nonopioid pain treatment and is “the first and only treatment of its kind to deliver prescription strength capsaicin directly into the skin,” according to Averitas Pharma, which will market the patch in the United States.

“Pain associated with diabetic neuropathy is an extremely challenging condition to diagnose, treat and manage effectively, which has a significant quality of life impact for many patients,” said David M. Simpson, MD, lead investigator of the STEP study that established the patch’s efficacy in this setting. He is professor of neurology at the Icahn School of Medicine at Mount Sinai, New York City.

“In addition, patients are dissatisfied with unresolved pain and the side effects associated with current systemic treatments,” noted Simpson in the company press release.

Continue reading